keyhole limpet hemocyanin
Biologicalexperimental
Keyhole limpet hemocyanin (KLH) is a large, multisubunit, oxygen-carrying, metalloprotein that is found in the hemolymph of the giant keyhole limpet, Megathura crenulata, a species of keyhole limpet that lives off the coast of California, from Monterey Bay to Isla Asuncion off Baja California. — Wikipedia
Clinical trial activity
41 trials · 40 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
19
Phase 3
7
Phase 4
3
Earliest trial started Jul 1, 1995 (NCT00019097)
Timeline
Indications
Approved for
Studied for
- Arthritis, Rheumatoid · Phase 2
- Autoimmune Diseases · Early Phase 1
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 3
- Dermatitis · Phase 1
- Dermatitis, Atopic · Phase 1
- Glioblastoma · Phase 3
- Glioma · Phase 2
- Gliosarcoma · Phase 3
- Healthy Volunteers · Phase 1
- HIV Infections · Phase 4
- Immunoproliferative Disorders · Phase 2
- Kidney Neoplasms · Phase 2
- Kidney Transplantation · Phase 4
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Non-Hodgkin · Phase 3
- Melanoma · Phase 1
- Multiple Myeloma · Phase 2
- Multiple Sclerosis · Phase 4
- Multiple Sclerosis, Relapsing-Remitting · Phase 3
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neoplasms, Nerve Tissue · Phase 1
- Neuroblastoma · Phase 1
- Ovarian Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 3
- Urologic Neoplasms · Phase 1
Mechanism of action
- Unspecified targetImmunity, active
immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaKeyhole limpet hemocyanin ↗
- ChEMBLCHEMBL5314988 ↗
Also known as
- biosyn klh
- immucothel
- immunocyanin
- immunocyanine
- keyhole-limpet haemocyanin
- keyhole-limpet hemacyanin
- keyhole limpet hemocyanin
- keyhole limpet hemocyanin
- keyhole limpet hemocyanin
- keyhole-limpet hemocyanin
- klh
- klh
- klh antigen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05876195 | N/A | Mar 1, 2023 | University of Oxford |
| NCT04079062 | Phase 1 | Sep 30, 2019 | Ono Pharmaceuticals |
| NCT03650114 | Phase 3 | Dec 21, 2018 | Novartis |
| NCT05845996 | Phase 1 | Nov 8, 2018 | Sanofi |
| NCT02754362 | Phase 2 | Jul 1, 2017 | Icahn School of Medicine at Mount Sinai, New York University |
| NCT02947854 | Phase 1 | Sep 1, 2016 | Covance, PCI Biotech AS |
| NCT02745756 | Phase 1 | Apr 14, 2016 | Johns Hopkins University, University of South Florida |
| NCT02545868 | Phase 3 | Oct 27, 2015 | Roche |
| NCT02079480 | Phase 1 | May 1, 2014 | Bristol-Myers Squibb |
| NCT01910662 | Phase 1 | Feb 22, 2013 | GlaxoSmithKline |
| NCT01509391 | N/A | Jan 1, 2012 | Medical University of Graz |
| NCT01498328 | Phase 2 | Dec 1, 2011 | Celldex Therapeutics |
| NCT01489956 | Early Phase 1 (Phase 1) | Dec 1, 2011 | Icahn School of Medicine at Mount Sinai, Immune Tolerance Network, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01480479 | Phase 3 | Nov 1, 2011 | Celldex Therapeutics |
| NCT01174082 | Phase 2 | Jul 20, 2010 | University of Texas at Houston |
| NCT01155791 | Phase 1 | Apr 1, 2010 | Stanford University |
| NCT00923910 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00536120 | Phase 4 | Jan 1, 2008 | Biogen |
| NCT00614731 | Phase 1 | Dec 1, 2007 | Atopic Dermatitis and Vaccinia Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Colorado, Denver |
| NCT00282308 | Phase 2 | Jan 1, 2006 | Genentech |
Showing 20 of 41 trials
Page 1 / 3
Organizations
Research & Development (40)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 9 | 2 | 2 | 1995 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 5 | 3 | 1999 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 3 | 1 | 2 | 2005 |
| University of Nebraska | Academic/Hospital | 3 | 3 | 1 | 1999 |
| Celldex Therapeutics | For profit | 2 | 2 | 2 | 2011 |
| Cornell University | Academic/Hospital | 2 | 2 | 2 | 1998 |
| Genitope Corporation | For profit | 2 | 1 | 2 | 1999 |
| New York University | Academic/Hospital | 2 | 1 | 2 | 2005 |
| Providence Health & Services | Academic/Hospital | 2 | 2 | 1 | 2003 |
| Roche | For profit | 2 | 2 | 2 | 2003 |
| Agouron | For profit | 1 | 1 | 1 | 1999 |
| Atopic Dermatitis and Vaccinia Network | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Biogen | For profit | 1 | 1 | 1 | 2008 |
| Biovest International | For profit | 1 | 1 | 1 | 2000 |
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2014 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Cascadian Therapeutics Inc. | For profit | 1 | 1 | 1 | 1999 |
| Covance | For profit | 1 | 0 | 1 | 2016 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2001 |
| Genentech | For profit | 1 | 1 | 1 | 2006 |
40 organizations
Page 1 / 2